The phase III ARAMIS study shows that the androgen-receptor antagonist 
darolutamide delays metastasis in men with castration-resistant prostate cancer 
by a median of 22 months compared with a placebo. Researchers also found that 
side effects associated with other drugs in this class were no more common in 
the placebo group than the darolutamide group.